Humanized anti-cll-1 antibodies

By recognizing and binding to CLL-1-expressing cells with humanized anti-CLL-1 antibodies, the problem of existing chemotherapy failing to effectively eliminate cancer stem cells has been solved, achieving specific targeting and inhibition of cancer cells and reducing the risk of cancer recurrence.

CN108290955BActive Publication Date: 2026-05-26OK THERAPEUTICS LTD
View PDF 36 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
OK THERAPEUTICS LTD
Filing Date
2016-11-22
Publication Date
2026-05-26

Smart Images

  • Figure CN108290955B_ABST
    Figure CN108290955B_ABST
Patent Text Reader

Abstract

The present application provides CLL-1 specific humanized antibodies.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Drier for silkscreen printed sheets

    EP0003089A1

  • Auristatin drug linker conjugates

    US20110020343A1

  • Grain-drill

    US323327A

  • Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element

    US4452720A

  • Target specific cross-linked heteroantibodies

    US4676980A